Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 2
1965 1
1966 1
1977 2
1979 1
1981 2
1986 2
1987 2
1989 1
1992 1
1998 1
2000 1
2001 1
2002 1
2003 3
2004 4
2005 7
2006 6
2007 7
2008 3
2009 7
2010 9
2011 10
2012 11
2013 7
2014 11
2015 10
2016 4
2017 7
2018 5
2019 6
2020 12
2021 9
2022 11
2023 8
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

157 results

Results by year

Filters applied: . Clear all
Page 1
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP, Poirier-Colame V, Roux A, Becharef S, Formenti S, Golden E, Cording S, Eberl G, Schlitzer A, Ginhoux F, Mani S, Yamazaki T, Jacquelot N, Enot DP, Bérard M, Nigou J, Opolon P, Eggermont A, Woerther PL, Chachaty E, Chaput N, Robert C, Mateus C, Kroemer G, Raoult D, Boneca IG, Carbonnel F, Chamaillard M, Zitvogel L. Vétizou M, et al. Science. 2015 Nov 27;350(6264):1079-84. doi: 10.1126/science.aad1329. Epub 2015 Nov 5. Science. 2015. PMID: 26541610 Free PMC article.
Fecal microbial transplantation from humans to mice confirmed that treatment of melanoma patients with antibodies against CTLA-4 favored the outgrowth of B. fragilis with anticancer properties. This study reveals a key role for Bacteroidales in the immunostimulatory effect …
Fecal microbial transplantation from humans to mice confirmed that treatment of melanoma patients with antibodies against CTLA-4 favored …
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.
Albiges L, Tannir NM, Burotto M, McDermott D, Plimack ER, Barthélémy P, Porta C, Powles T, Donskov F, George S, Kollmannsberger CK, Gurney H, Grimm MO, Tomita Y, Castellano D, Rini BI, Choueiri TK, Saggi SS, McHenry MB, Motzer RJ. Albiges L, et al. ESMO Open. 2020 Nov;5(6):e001079. doi: 10.1136/esmoopen-2020-001079. ESMO Open. 2020. PMID: 33246931 Free PMC article. Clinical Trial.
Efficacy endpoints included overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) per independent radiology review committee in patients with intermediate/poor-risk disease (I/P; primary), intent-to-treat patients (ITT; secondary) and in patient …
Efficacy endpoints included overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) per independent radiolo …
Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
Brennan B, Kirton L, Marec-Bérard P, Gaspar N, Laurence V, Martín-Broto J, Sastre A, Gelderblom H, Owens C, Fenwick N, Strauss S, Moroz V, Whelan J, Wheatley K. Brennan B, et al. Lancet. 2022 Oct 29;400(10362):1513-1521. doi: 10.1016/S0140-6736(22)01790-1. Lancet. 2022. PMID: 36522207 Clinical Trial.
Event-free survival at 3 years was 61% with group 1 and 67% with group 2 (adjusted hazard ratio [HR] 0.71 [95% credible interval 0.55-0.92 in favour of group 1). The probability that the true HR was less than 1.0 was greater than 0.99. ...
Event-free survival at 3 years was 61% with group 1 and 67% with group 2 (adjusted hazard ratio [HR] 0.71 [95% credible interval 0.55-0.92 i …
Médecins du monde et le principe d’universalisme proportionné appliqué à la prévention du cancer du col de l’utérus.
Laurence S, Lallemand A, Chappuis M, Rochefort J. Laurence S, et al. Sante Publique. 2020;2(HS2):53-57. doi: 10.3917/spub.197.0053. Sante Publique. 2020. PMID: 35724228 French.
MDM diversifies screening options by inviting women to perform a self-collected vaginal swab for high risk HPV testing.This multi-level intervention aims to create favorable conditions for public participation and empowerment by promoting specifically tailored tools and a …
MDM diversifies screening options by inviting women to perform a self-collected vaginal swab for high risk HPV testing.This multi-level inte …
Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.
Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S, Yamamoto T, Mamedov A, Loblaw A. Klotz L, et al. J Clin Oncol. 2015 Jan 20;33(3):272-7. doi: 10.1200/JCO.2014.55.1192. Epub 2014 Dec 15. J Clin Oncol. 2015. PMID: 25512465 Free article.
PURPOSE: Active surveillance is increasingly accepted as a treatment option for favorable-risk prostate cancer. Long-term follow-up has been lacking. ...This mortality rate is consistent with expected mortality in favorable-risk patients managed with initial definit …
PURPOSE: Active surveillance is increasingly accepted as a treatment option for favorable-risk prostate cancer. Long-term follow-up h …
Cross-reactivity between microbial and tumor antigens.
Zitvogel L, Kroemer G. Zitvogel L, et al. Curr Opin Immunol. 2022 Apr;75:102171. doi: 10.1016/j.coi.2022.102171. Epub 2022 Feb 24. Curr Opin Immunol. 2022. PMID: 35219942 Review.
In addition, microbial antigens can elicit specific T lymphocyte responses that are cross-reactive with respect to tumor-associated antigens, hence inducing specific antitumor immune responses. Here, we discuss current evidence in favor of such cross-reactive anticancer/an …
In addition, microbial antigens can elicit specific T lymphocyte responses that are cross-reactive with respect to tumor-associated antigens …
First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial.
Albiges L, Tannir NM, Burotto M, McDermott D, Plimack ER, Barthélémy P, Porta C, Powles T, Donskov F, George S, Kollmannsberger CK, Gurney H, Grimm MO, Tomita Y, Castellano D, Rini BI, Choueiri TK, Leung D, Saggi SS, Lee CW, McHenry MB, Motzer RJ. Albiges L, et al. Eur Urol. 2022 Mar;81(3):266-271. doi: 10.1016/j.eururo.2021.10.001. Epub 2021 Nov 5. Eur Urol. 2022. PMID: 34750035 Free PMC article. Clinical Trial.
With minimum study follow-up of 4 yr for intent-to-treat patients, OS favored NIVO+IPI (n = 53) over sunitinib (n = 55; hazard ratio 0.63, 95% confidence interval 0.40-1.0) among patients without prior nephrectomy. ...
With minimum study follow-up of 4 yr for intent-to-treat patients, OS favored NIVO+IPI (n = 53) over sunitinib (n = 55; hazard ratio …
Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study.
ASTEC study group; Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. ASTEC study group, et al. Lancet. 2009 Jan 10;373(9658):125-36. doi: 10.1016/S0140-6736(08)61766-3. Epub 2008 Dec 16. Lancet. 2009. PMID: 19070889 Free PMC article. Clinical Trial.
FINDINGS: After a median follow-up of 37 months (IQR 24-58), 191 women (88 standard surgery group, 103 lymphadenectomy group) had died, with a hazard ratio (HR) of 1.16 (95% CI 0.87-1.54; p=0.31) in favour of standard surgery and an absolute difference in 5-year overall su …
FINDINGS: After a median follow-up of 37 months (IQR 24-58), 191 women (88 standard surgery group, 103 lymphadenectomy group) had died, with …
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.
Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Dyagil I, Glushko N, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Reilly L, Jeynes-Ellis A, Leip E, Bardy-Bouxin N, Hochhaus A, Brümmendorf TH. Cortes JE, et al. J Clin Oncol. 2018 Jan 20;36(3):231-237. doi: 10.1200/JCO.2017.74.7162. Epub 2017 Nov 1. J Clin Oncol. 2018. PMID: 29091516 Free PMC article. Clinical Trial.
Results The major molecular response (MMR) rate at 12 months (primary end point) was significantly higher with bosutinib versus imatinib (47.2% v 36.9%, respectively; P = .02), as was complete cytogenetic response (CCyR) rate by 12 months (77.2% v 66.4%, respectively; P = .0075). …
Results The major molecular response (MMR) rate at 12 months (primary end point) was significantly higher with bosutinib versus imatinib (47 …
Beneficial autoimmunity improves cancer prognosis.
Zitvogel L, Perreault C, Finn OJ, Kroemer G. Zitvogel L, et al. Nat Rev Clin Oncol. 2021 Sep;18(9):591-602. doi: 10.1038/s41571-021-00508-x. Epub 2021 May 11. Nat Rev Clin Oncol. 2021. PMID: 33976418 Review.
Importantly, despite the undesirable effects of these symptoms, such events can have prognostic value and correlate with favourable disease outcomes, suggesting 'beneficial autoimmunity'. Similarly, the occurrence of dermal and endocrine autoimmune adverse events in patien …
Importantly, despite the undesirable effects of these symptoms, such events can have prognostic value and correlate with favourable d …
157 results